ClinicalTrials.gg
CompletedNCT03404908Updated Nov 24, 2023

TAP vs QLB in Patients After Cesarean Delivery

A Phase 4 interventional study of TAP (transversus abdominis plane block) and QL (quadratus lumborum block) in Cesarean Section and Postoperative Pain, sponsored by Medical University of Lublin. Completed at 1 site in Poland. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Medical University of Lublin · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Pain, Postoperative with a site in Poland — 8 open to participants now, 9 under way, none of them phase 3. Pain, Postoperative · Poland.

Enrollment
20th of 45
105 · median 104
Started
2018
with 6 others
Phase 4
16 of 48
2 open now
Registered
20th of 48
by date
Lead sponsor
7 of 48
Medical University of Lublin

Among the 48 studies in Pain, Postoperative with a site in Poland, this one is the 20th largest by enrollment of the 45 interventional ones that give a count, is one of 7 that started in 2018, is one of 16 in phase 4, and was the 20th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 48 studies in Pain, Postoperative with a site in Poland are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Pain, Postoperative with a site in Poland, or all of them as a file.
02

Study summary

Comparison of two types of analgesia after cesarean section All patients will be anesthetized with spinal technique. Ultrasound-guided transversus abdominis plane or quadratus lumborum block to treat postoperative pain. Postoperative pain will be measured with visual-analog scale (VAS). 1, 2, 6 months after surgery each patient will be called to assess neuropathic pain with Neuropathic Pain Symptom Inventory (NPSI).

Read the detailed description

Written consent will be obtained before the cesarean section. Only subarachnoidally anesthetized patients may participate in the study. Pencil-point spinal needle and bupivacaine (Marcaine Heavy Spinal 0.5 %) will be used.

At the end of surgery ultrasound-guided regional block will be performed. Each patient will be randomly allocated to one of the treated group: transversus abdominis plane block (TAP) or quadratus lumborum (QL). Patients receive 0.2 mL of local anesthetic solution (0.375 % ropivacaine) on each side.

Postoperative pain will be measured with VAS (visual-analog scale) 2, 4, 8, 12 and 24 hours after the end of the operation.

Paracetamol, metamizole, ketoprofen may be given as required. Whenever pain exceeds 40 (VAS) 5 mg of morphine will be given intravenously (maximum two dosages per day).

1, 3, 6 months patients will be called to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.

03

Conditions studied

  • Cesarean Section
  • Postoperative Pain

Keywords

  • transversus abdominis plane block
  • quadratus lumborum block
  • neuropathic pain
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained consent
  • singleton pregnancy
  • subarachnoid anesthesia

Exclusion criteria

Exclusion Criteria:

  • coagulopathy
  • allergy to local anesthetics
  • depression, antidepressant drugs treatment
  • epilepsy
  • usage of painkiller before surgery
  • addiction to alcohol or recreational drugs
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    TAP

    Ultrasound-guided transversus abdominis plane block at the end of cesarean section

    Procedure: TAP (transversus abdominis plane block) · Drug: Ropivacaine · Device: Needle · Drug: paracetamol · Drug: metamizole · Drug: Ketoprofen · Drug: Morphine

  • Experimental
    QLB

    Ultrasound-guided quadratus lumborum block at the end of cesarean section

    Procedure: QL (quadratus lumborum block) · Drug: Ropivacaine · Device: Needle · Drug: paracetamol · Drug: metamizole · Drug: Ketoprofen · Drug: Morphine

Interventions

  • ProcedureTAP (transversus abdominis plane block)

    the ultrasound-guided regional block of abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.375% ropivacaine administered (0.2 mL/kg).

  • ProcedureQL (quadratus lumborum block)

    the ultrasound-guided regional block of abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with a distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).

  • In both groups (TAP\&QLB) 0.375% ropivacaine will be given (0.2 mL/kg)

  • DeviceNeedle

    Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study

  • Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day

  • Intravenous metamizole will be used (1.0 gram), up to 4 grams per day

  • Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day

  • Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)

06

What researchers measure

Primary outcomes

  1. Postoperative pain

    Acute pain measured with VAS (visual-analogue scale). VAS in milimmeters. Minimum value 0, maximum 100. Less better - less severe pain. 0 no pain at all.

    Time frame: up to 24 hours after the surgery

Secondary outcomes

  1. Neuropathic pain

    Neuropathic pain occurrence assessed with Neuropathic Pain Symptom Inventory (NPSI) 10 descriptive variables, each one from 0 to 10. 0 means no pain. 10 very high chance of occurrence of neuropathic pain.

    Time frame: 6 months from the surgery

07

Study locations

1 site
  • II Department of Anesthesia and Intensive Care, Medical University of Lublin
    Lublin, 20-081, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Jan 2019, 11 months.

Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 11 months is below that.

Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 19, 2018
StartActual
Feb 7, 2018
Primary completionActual
Jan 14, 2019
CompletionActual
Apr 17, 2019
Last update
Nov 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03404908
Lead sponsor
Medical University of Lublin
Responsible party
Michał Borys (associate professor, Medical University of Lublin) — Principal investigator
First posted
Jan 19, 2018
Start date
Feb 7, 2018
Primary completion
Jan 14, 2019
Completion
Apr 17, 2019
Last update
Nov 24, 2023

Study contacts

Mirosław Czuczwar, M.D., PhD
study chair · Medical University of Lublin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion